Testosterone attenuates and the selective estrogen receptor modulator, raloxifene, potentiates amphetamine-induced locomotion in male rats

Hormones and Behavior

Volumn 70, Issue , 2015, Pages 73-84

  Purves Tyson, Tertia D ^a,b,d   Boerrigter, Danny ^b   Allen, Katherine ^a,b,d   Zavitsanou, Katerina ^a,b,d   Karl, Tim ^b,d   Djunaidi, Vanezha ^a,b,d   Double, Kay L ^c   Desai, Reena ^e   Handelsman, David J ^e   Weickert, Cynthia Shannon ^a,b,d  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adolescence; Androgen; Dopamine; Locomotion; Psychosis; Sex steroids; Testosterone

Indexed keywords

AMPHETAMINE; RALOXIFENE; SODIUM CHLORIDE; TESTOSTERONE; CENTRAL STIMULANT AGENT; DOPAMINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONFORMATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; GONADECTOMY; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; ORGAN WEIGHT; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; SEMINAL VESICLE; SHAM PROCEDURE; TREATMENT DURATION; ANATOMY AND HISTOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NEOSTRIATUM; ORCHIECTOMY; ORGAN SIZE; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; NEOSTRIATUM; ORCHIECTOMY; ORGAN SIZE; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEMINAL VESICLES; TESTOSTERONE;

EID: 84925433058     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2015.02.005     Document Type: Article

References (61)

1. Arnsten A.F. The neurobiology of thought: the groundbreaking discoveries of Patricia Goldman-Rakic 1937-2003. Cereb. Cortex 2013, 23:2269-2281.
2. Beatty W.W., Dodge A.M., Traylor K.L. Stereotyped behavior elicited by amphetamine in the rat: influences of the testes. Pharmacol. Biochem. Behav. 1982, 16:565-568.
3. Bolanos C.A., Glatt S.J., Jackson D. Subsensitivity to dopaminergic drugs in periadolescent rats: a behavioral and neurochemical analysis. Brain Res. Dev. Brain Res. 1998, 111:25-33.
4. Boulware M.I., Weick J.P., Becklund B.R., Kuo S.P., Groth R.D., Mermelstein P.G. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J. Neurosci. 2005, 25:5066-5078.
5. Brisch R., Saniotis A., Wolf R., Bielau H., Bernstein H.G., Steiner J., Bogerts B., Braun A.K., Jankowski Z., Kumaritlake J., Henneberg M., Gos T. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front. Psychol. 2014, 5:47.
6. Byrne J.H., Voogt M., Turner K.M., Eyles D.W., McGrath J.J., Burne T.H. The impact of adult vitamin D deficiency on behaviour and brain function in male Sprague-Dawley rats. PLoS One 2013, 8:e71593.
7. Celotti F., Melcangi R.C., Martini L. The 5 alpha-reductase in the brain: molecular aspects and relation to brain function. Front. Neuroendocrinol. 1992, 13:163-215.
8. Christie K.A., Burke J.D., Regier D.A., Rae D.S., Boyd J.H., Locke B.Z. Epidemiologic evidence for early onset of mental disorders and higher risk of drug abuse in young adults. Am. J. Psychiatry 1988, 145:971-975.
9. Creutz L.M., Kritzer M.F. Mesostriatal and mesolimbic projections of midbrain neurons immunoreactive for estrogen receptor beta or androgen receptors in rats. J. Comp. Neurol. 2004, 476:348-362.
10. de Souza Silva M.A., Mattern C., Topic B., Buddenberg T.E., Huston J.P. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. Eur. Neuropsychopharmacol. 2009, 19:53-63.
11. Devoto P., Frau R., Bini V., Pillolla G., Saba P., Flore G., Corona M., Marrosu F., Bortolato M. Inhibition of 5alpha-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. Psychoneuroendocrinology 2012, 37:1630-1645.
12. Di Giovanni G., Esposito E., Di Matteo V. Role of serotonin in central dopamine dysfunction. CNS Neurosci. Ther. 2010, 16:179-194.
13. Dluzen D.E., Ramirez V.D. Effects of orchidectomy on nigro-striatal dopaminergic function: behavioral and physiological evidence. J. Neuroendocrinol. 1989, 1:285-290.
14. Duschek E.J., Gooren L.J., Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur. J. Endocrinol. 2004, 150:539-546.
15. Field A. Discovering statistics with SPSS. ISM introdusing statistical methods 2005, Sage, London. Second ed. B. Wright (Ed.).
16. Forgie M.L., Stewart J. Six differences in the locomotor-activating effects of amphetamine: role of circulating testosterone in adulthood. Physiol. Behav. 1994, 55:639-644.
17. Frau R., Bini V., Pes R., Pillolla G., Saba P., Devoto P., Bortolato M. Inhibition of 17alpha-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation. Psychoneuroendocrinology 2014, 39:204-213.
18. Gainetdinov R.R., Caron M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 2003, 43:261-284.
19. Harwood D.T., Handelsman D.J. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin. Chim. Acta 2009, 409:78-84.
20. Heikkila R.E., Orlansky H., Cohen G. Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices. Biochem. Pharmacol. 1975, 24:847-852.
21. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 1998, 18:1979-1986.
22. Kritzer M.F., Creutz L.M. Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J. Neurosci. 2008, 28:9525-9535.
23. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch. Womens Ment. Health 2002, 5:99-104.
24. Lammers C.H., D'Souza U., Qin Z.H., Lee S.H., Yajima S., Mouradian M.M. Regulation of striatal dopamine receptors by estrogen. Synapse 1999, 34:222-227.
25. Lapin I.P., Rogawski M.A. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice. Behav. Brain Res. 1995, 70:145-151.
26. Laviola G., Adriani W., Terranova M.L., Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci. Biobehav. Rev. 1999, 23:993-1010.
27. Leyton M., Vezina P. Dopamine ups and downs in vulnerability to addictions: a neurodevelopmental model. Trends Pharmacol. Sci. 2014, 35:268-276.
28. Markham J.A. Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord. 2012, 13:187-207.
29. McNamara K.M., Harwood D.T., Simanainen U., Walters K.A., Jimenez M., Handelsman D.J. Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry. J. Steroid Biochem. Mol. Biol. 2010, 121:611-618.
30. Menniti F.S., Baum M.J. Differential effects of estrogen and androgen on locomotor activity induced in castrated male rats by amphetamine, a novel environment, or apomorphine. Brain Res. 1981, 216:89-107.
31. Morris R.W., Fung S.J., Rothmond D.A., Richards B., Ward S., Noble P.L., Woodward R.A., Weickert C.S., Winslow J.T. The effect of gonadectomy on prepulse inhibition and fear-potentiated startle in adolescent rhesus macaques. Psychoneuroendocrinology 2010, 35:896-905.
32. Napolitano A., Cesura A.M., Da Prada M. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J. Neural Transm. Suppl. 1995, 45:35-45.
33. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 1996, 16:436-447.
34. O'Neill M.F., Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berlin) 1999, 145:237-250.
35. Pehrson A.L., Moghaddam B. Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion. Psychopharmacology (Berlin) 2010, 211:443-455.
36. Perez S.E., Chen E.Y., Mufson E.J. Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain. Brain Res. Dev. Brain Res. 2003, 145:117-139.
37. Purves-Tyson T.D., Arshi M.S., Handelsman D.J., Cheng Y., Keast J.R. Androgen and estrogen receptor-mediated mechanisms of testosterone action in male rat pelvic autonomic ganglia. Neuroscience 2007, 148:92-104.
38. Purves-Tyson T.D., Handelsman D.J., Double K.L., Owens S.J., Bustamante S., Weickert C.S. Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neurosci. 2012, 13:95.
39. Purves-Tyson T.D., Owens S.J., Double K.L., Desai R., Handelsman D.J., Weickert C.S. Testosterone induces molecular changes in dopamine signaling pathway molecules in the adolescent male rat nigrostriatal pathway. PLoS One 2014, 9:e91151.
40. Randrup A., Munkvad I. Pharmacology and physiology of stereotyped behavior. J. Psychiatr. Res. 1974, 11:1-10.
41. Ravizza T., Galanopoulou A.S., Veliskova J., Moshe S.L. Sex differences in androgen and estrogen receptor expression in rat substantia nigra during development: an immunohistochemical study. Neuroscience 2002, 115:685-696.
42. Richards A.B., Morris R.W., Ward S., Schmitz S., Rothmond D.A., Noble P.L., Woodward R.A., Winslow J.T., Weickert C.S. Gonadectomy negatively impacts social behavior of adolescent male primates. Horm. Behav. 2009, 56:140-148.
43. Rouge-Pont F., Usiello A., Benoit-Marand M., Gonon F., Piazza P.V., Borrelli E. Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J. Neurosci. 2002, 22:3293-3301.
44. Saksena S.K., Lau I.F. Variations in serum androgens, estrogens, progestins, gonadotropins and prolactin levels in male rats from prepubertal to advanced age. Exp. Aging Res. 1979, 5:179-194.
45. Salahpour A., Ramsey A.J., Medvedev I.O., Kile B., Sotnikova T.D., Holmstrand E., Ghisi V., Nicholls P.J., Wong L., Murphy K., Sesack S.R., Wightman R.M., Gainetdinov R.R., Caron M.G. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4405-4410.
46. Sanchez M.G., Bourque M., Morissette M., Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:e43-e71.
47. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 1993, 33:639-677.
48. Sharp T., Zetterstrom T., Ljungberg T., Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res. 1987, 401:322-330.
49. Shughrue P.J., Lane M.V., Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J. Comp. Neurol. 1997, 388:507-525.
50. Singh J., O'Neill C., Handelsman D.J. Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology 1995, 136:5311-5321.
51. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 1995, 15:4102-4108.
52. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75:406-433.
53. Teicher M.H., Barber N.I., Gelbard H.A., Gallitano A.L., Campbell A., Marsh E., Baldessarini R.J. Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology 1993, 9:147-156.
54. Thiblin I., Finn A., Ross S.B., Stenfors C. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br. J. Pharmacol. 1999, 126:1301-1306.
55. Uebelhart B., Herrmann F., Pavo I., Draper M.W., Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2004, 19:1518-1524.
56. Usall J., Huerta-Ramos E., Iniesta R., Cobo J., Araya S., Roca M., Serrano-Blanco A., Teba F., Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2011, 72:1552-1557.
57. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., Piazza P.V., Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000, 408:199-203.
58. Walker D.M., Kirson D., Perez L.F., Gore A.C. Molecular profiling of postnatal development of the hypothalamus in female and male rats. Biol. Reprod. 2012, 87:129.
59. Weickert C.S., Miranda-Angulo A.L., Wong J., Perlman W.R., Ward S.E., Radhakrishna V., Straub R.E., Weinberger D.R., Kleinman J.E. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 2008, 17:2293-2309.
60. Weickert T.W., Weinberg D., Lenroot R., Catts S.V., Wells R., Vercammen A., O'Donnell M., Galletly C., Liu D., Balzan R., Short B., Pellen D., Curtis J., Carr V.J., Kulkarni J., P.R., S., Weickert C.S. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol. Psychiatry 2015, (in Press).
61. Wu X., Glinn M.A., Ostrowski N.L., Su Y., Ni B., Cole H.W., Bryant H.U., Paul S.M. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 1999, 847:98-104.